Aytu Biopharma (AYTU) Retained Earnings (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Retained Earnings data on file, last reported at -$347.8 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$347.8 million, down 10.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$347.8 million (down 10.86% YoY), and the FY2025 annual result was -$333.5 million, down 4.24% from the prior year.
• Retained Earnings slipped to -$347.8 million in Q1 2026 per AYTU's latest filing, from -$342.2 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$270.8 million in Q1 2022 and troughed at -$347.8 million in Q1 2026.
• A 5-year average of -$312.4 million and a median of -$313.7 million in 2025 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 61.01% in 2022, then grew 0.52% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$294.5 million in 2022, then fell by 6.11% to -$312.5 million in 2023, then decreased by 1.67% to -$317.7 million in 2024, then dropped by 7.69% to -$342.2 million in 2025, then slipped by 1.64% to -$347.8 million in 2026.
• Business Quant data shows AYTU's Retained Earnings at -$347.8 million in Q1 2026, -$342.2 million in Q4 2025, and -$331.6 million in Q3 2025.